26/10/2014 00:27:40 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
10/24/20149:33AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Friday's session are United Parcel Service Inc. (UPS), Amazon.com Inc. (AMZN) and Procter & Gamble Co. (PG). United Parcel Service Inc. said its revenue rose 5.7% in the latest quarter, helped by higher daily package volumes and strength overseas. Shares... More...>>
10/24/20148:32AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Fall After N.Y.C. Ebola News; P&G Shares Gain
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- U.S. stock futures signaled modest losses for Wall Street on Friday, with the pullback coming after news of New York's first reported case of Ebola. Corporate quarterly results, however, remain in focus, as the latest reports are scheduled to come from Procter & Gamble... More...>>
10/24/20147:30AMBWBristol-Myers Squibb Reports Third Quarter 2014 Financial Results
Posts Third Quarter GAAP EPS of $0.43 and Non-GAAP EPS of $0.45 Achieves Significant Regulatory Milestones for PD-1 Inhibitor Opdivo Launches Daklinza-Based Regimens for HCV Patients in Japan and Europe Adjusts 2014 GAAP EPS Guidance Range to $1.15 - $1.25 and Confirms Non-GAAP EPS Guidance Range of $1.70 - $1.80 Bristol-Myers... More...>>
10/24/20147:03AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Slips After NY Ebola News; P&G Results Due
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- U.S. stock futures indicated modest losses for Wall Street at the open on Friday, with the pullback coming after news of New York's first reported case of Ebola. The week of sharp swings in the market will wrap up with results from Procter & Gamble Co. and Ford Motor... More...>>
10/24/20145:52AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Slip; P&G, Ford Results Due
By Carla Mozee, MarketWatch LONDON (MarketWatch) -- U.S. stock futures indicated modest losses for Wall Street at the open on Friday, with investors set to wrap up a week of sharp swings in the market with results from Procter & Gamble Co., the consumer-products giant that makes up part of the Dow Jones Industrial... More...>>
10/19/20145:47AMDJNMARKET SNAPSHOT: More Than 1/3 of Dow Stocks To Report This Week
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- Weakness in Europe and a stronger dollar are the major concerns for corporate America going into this earnings season but that may apply more to outlooks than results for the third quarter. Stocks are coming off a roller coaster week going into the heart... More...>>
10/13/20149:00AMBWBristol-Myers Squibb to Hold Investor Teleconference to Discuss CMSTO Highlights
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Friday, October 31, 2014, at 2:30 p.m. EDT (1:30 p.m. CDT) to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) in Chicago. Company executives will provide an overview of data presented at the meeting, with... More...>>
10/13/20148:00AMBWBristol-Myers Squibb, Pharmacyclics & Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) & IMBRUVICA®(...
Bristol-Myers Squibb Company (NYSE:BMY), Pharmacyclics, Inc. (NASDAQ:PCYC), and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint... More...>>
10/08/20148:00AMBWBristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S.
Bristol-Myers Squibb Company (NYSE:BMY) has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva (efavirenz) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) products. Accordingly, we believe that loss of exclusivity in the... More...>>
10/07/201410:00AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Tuesday's session are SodaStream International Ltd. (SODA), Christopher & Banks Corp. (CBK) and General Motors Co. (GM). SodaStream on Tuesday projected sharply lower-than-expected revenue for the third quarter, as weak demand for its soda makers and flavors... More...>>
10/07/20148:30AMBWBristol-Myers Squibb Statement about Asunaprevir in the U.S.
Given the rapidly evolving hepatitis C (HCV) treatment landscape in the U.S., Bristol-Myers Squibb (NYSE:BMY) has decided that it will not pursue U.S. Food and Drug Administration (FDA) approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States and has... More...>>
10/06/20148:00AMBWBristol-Myers Squibb Announces Collaboration to Evaluate Opdivo (nivolumab) in Combination with Targeted Therapies from Novar...
Studies will evaluate Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Novartis’ Zykadia (ceritinib), INC280 and EGF816 Bristol-Myers Squibb Company (NYSE:BMY) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability... More...>>
10/06/20148:00AMBWBristol-Myers Squibb & MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia...
Bristol-Myers Squibb Company (NYSE:BMY) and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as... More...>>
10/03/20148:00AMBWBristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014™ Showcasing Continued Innovation in Virology
Continued Development of Investigational HIV Attachment Inhibitor Underscores BMS’ Commitment to HIV Research Efficacy, Safety, and Drug Interaction Profile of Investigational NS5A replication inhibitor Daclatasvir Studied in Multiple Hepatitis C Treatment Regimens and Patient Groups Bristol-Myers Squibb Company (NYSE:BMY... More...>>
10/01/201410:00AMBWBristol-Myers Squibb to Announce Results for Third Quarter on October 24
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter on Friday, October 24, 2014. During a conference call at 10:30 a.m. EDT on October 24, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are invited... More...>>
10/01/20149:47AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Wednesday's session are Amazon.com Inc. (AMZN), RCS Capital Corp. (RCAP) and Babcock & Wilcox Co. (BWC). Amazon.com appears to be close to settling a nearly two-month dispute with Walt Disney Co. (DIS) during which the e-commerce giant stopped offering Disney... More...>>
09/30/20145:00PMBWBristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations to Prudential
Transfers liabilities and related assets for approximately 8,000 U.S. retirees and their beneficiaries Benefits entrusted to a global financial institution with expertise in long-term management of retirement benefits Bristol-Myers Squibb Company (NYSE:BMY) today announced it will settle $1.4 billion in pension obligations... More...>>
09/29/20148:21AMBWEuropean Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer
First completed regulatory submission for a PD-1 immune checkpoint inhibitor in lung cancer Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for nivolumab in non-small cell lung cancer (NSCLC) – the... More...>>
09/29/20143:00AMBWPositive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presen...
Objective response rate was 32% in Opdivo treated patients and 11% in the reference arm of chemotherapy-treated patients Majority (95%) of responses were ongoing in Opdivo treated patients and median duration of response was not reached Overall frequency of adverse events was lower with Opdivo compared to chemotherapy;... More...>>
09/26/20144:18PMBWBristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union
FDA accepts for priority review the Biologics License Application for previously treated advanced melanoma, based on data from first Phase 3 randomized trial of a PD-1 immune checkpoint inhibitor; agency grants second breakthrough therapy designation for Opdivo European Medicines Agency validates the marketing authorization... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy141026 00:27